The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA
Open accessAbstract
Endosomal sequestration of lipid-based nanoparticles (LNPs) remains a formidable barrier to delivery. Herein, structure-activity analysis of cholesterol analogues reveals that incorporation of C-24 alkyl phytosterols into LNPs (eLNPs) enhances gene transfection and the length of alkyl tail, flexibility of sterol ring and polarity due to -OH group is required to maintain high transfection. Cryo-TEM displays a polyhedral shape for eLNPs compared to spherical LNPs, while x-ray scattering shows little disparity in internal structure. eLNPs exhibit higher cellular uptake and retention, potentially leading to a steady release from the endosomes over time. 3D single-particle tracking shows enhanced intracellular diffusivity of eLNPs relative to LNPs, suggesting eLNP traffic to productive pathways for escape. Our findings show the importance of cholesterol in subcellular transport of LNPs carrying mRNA and emphasize the need for greater insights into surface composition and structural properties of nanoparticles, and their subcellular interactions which enable designs to improve endosomal escape.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other researchers propose that the outer shell of mRNA-LNPs consists of one or multiple bilayers, based on cryo-TEM analysis (Fig. 2) (Patel et al., 2020, Tanaka et al., 2020) or SANS (Sebastiani et al., 2021).”
From mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability (2021) · cites this paper as Patel et al., 2020
Experimental — accuracy not yet measuredIn the citing paper
“In mRNA-LNP formulations, such as those used in mRNA vaccines, the fraction of accessible mRNA is very low (Yanez Arteta et al., 2018, Patel et al., 2020) and thus, encapsulation efficiencies, derived from RiboGreen assays, are typically > 90%.”
From mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability (2021) · cites this paper as Patel et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
Zheng, S. Q., Palovcak, E. J., Armache, J., Verba, K. A., Cheng, Y., & Agard, D. A. (2017) · Nature Methods · doi:10.1038/nmeth.4193 · Cited by 7,496
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
An Inverted Hexagonal Phase of Cationic Liposome-DNA Complexes Related to DNA Release and Delivery
Koltover, I., Salditt, T., Rädler, J. O., & Safinya, C. R. (1998) · Science · doi:10.1126/science.281.5373.78 · Cited by 1,336
Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
Carette, J. E., Raaben, M., Wong, A., Herbert, A. S., Obernosterer, G., Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G. T., et al. (2011) · Nature · doi:10.1038/nature10348 · Cited by 1,327
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Moreau, R. A., Whitaker, B. D., & Hicks, K. B. (2002) · Progress in Lipid Research · doi:10.1016/s0163-7827(02)00006-1 · Cited by 1,162
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Chemistry of Lipid Nanoparticles for RNA Delivery
Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 917
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 744
Liu, S., Cheng, Q., Wei, T., Yu, X., Johnson, L. T., Farbiak, L., & Siegwart, D. J. (2021) · Nature Materials · doi:10.1038/s41563-020-00886-0 · Cited by 653
“Acknowledging that DLin-MC3-DMA (used in FDA-approved Onpattro) LNPs were optimized for siRNA 50 and not mRNA delivery, DLin-MC3-DMA LNPs provide value as a reference 15, 51 .”
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 649
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Endosomal escape: A bottleneck for LNP-mediated therapeutics
Chatterjee, S., Kon, E., Sharma, P., & Peer, D. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307800120 · Cited by 628
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 609
Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514
Self-citationOptimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
Lokugamage, M. P., Vanover, D. A., Beyersdorf, J. P., Hatit, M. Z. C., Rotolo, L., Echeverri, E. S., Peck, H. E., Ni, H., Yoon, J., Kim, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00786-x · Cited by 539
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 537
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 506
Lee, Y., Jeong, M., Park, J., Jung, H., & Lee, H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01086-x · Cited by 493
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
Microfluidic formulation of nanoparticles for biomedical applications
Shepherd, S. J., Issadore, D., & Mitchell, M. J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120826 · Cited by 465
Sebastiani, F., Yanez Arteta, M., Lerche, M., Porcar, L., Lang, C., Bragg, R. A., Elmore, C. S., Krishnamurthy, V. R., Russell, R. A., Darwish, T., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10064 · Cited by 409
Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles
Schlich, M., Palomba, R., Costabile, G., Mizrahy, S., Pannuzzo, M., Peer, D., & Decuzzi, P. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10213 · Cited by 387
Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery
Eygeris, Y., Patel, S., Jozić, A., & Sahay, G. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01386 · Cited by 397
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Kon, E., Ad‐El, N., Hazan‐Halevy, I., Stotsky‐Oterin, L., & Peer, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00811-9 · Cited by 393
Impact of lipid nanoparticle size on mRNA vaccine immunogenicity
Hassett, K. J., Higgins, J. S., Woods, A., Levy, B., Xia, Y., Hsiao, C. J., Acosta, E. P., Almarsson, Ö., Moore, M. J., & Brito, L. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.021 · Cited by 382
Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery
Maeki, M., Uno, S., Niwa, A., Okada, Y., & Tokeshi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.017 · Cited by 359
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282
LoPresti, S. T., Arral, M. L., Chaudhary, N., & Whitehead, K. A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.046 · Cited by 293
Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation
Kim, J., Jozić, A., Lin, Y., Eygeris, Y., Bloom, E., Tan, X., Acosta, C., MacDonald, K. D., Welsher, K., & Sahay, G. (2022) · ACS Nano · doi:10.1021/acsnano.2c05647 · Cited by 292
Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation
Su, K., Shi, L., Sheng, T., Yan, X., Lin, L., Meng, C., Wu, S., Chen, Y., Zhang, Y., Wang, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50093-7 · Cited by 292
Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
Zheng, L., Bandara, S. R., Tan, Z., & Leal, C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301067120 · Cited by 283
Lipid Nanoparticle–mRNA Formulations for Therapeutic Applications
Wang, C., Zhang, Y., & Dong, Y. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00550 · Cited by 276
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H. A., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 271
Zhang, R., El-Mayta, R. D., Murdoch, T. J., Warzecha, C. C., Billingsley, M. M., Shepherd, S. J., Gong, N., Wang, L., Wilson, J. M., Lee, D., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm01609h · Cited by 267
Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy
Guevara, M. L., Persano, F., & Persano, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.589959 · Cited by 261
Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery
Nogueira, S. S., Schlegel, A., Maxeiner, K., Weber, B., Barz, M., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Ramishetti, S., Peer, D., et al. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c01834 · Cited by 252
Lipid nanoparticles in the development of mRNA vaccines for COVID-19
Wilson, B., & Geetha, K. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103553 · Cited by 265
Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Delivery
Sun, D., & Lu, Z. (2023) · Pharmaceutical Research · doi:10.1007/s11095-022-03460-2 · Cited by 253
Zhang, D., Wang, G., Yu, X., Wei, T., Farbiak, L., Johnson, L. T., Taylor, A. M., Xu, J., Hong, Y., Zhu, H., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01122-3 · Cited by 243
Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 248
Strategies to reduce the risks of mRNA drug and vaccine toxicity
Bitounis, D., Jacquinet, E., Rogers, M. A., & Amiji, M. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00859-3 · Cited by 242
Álvarez‐Benedicto, E., Farbiak, L., Ramírez, M. M., Wang, X., Johnson, L. T., Mian, O. T., Guerrero, E. D., & Siegwart, D. J. (2021) · Biomaterials Science · doi:10.1039/d1bm01454d · Cited by 235
Jeong, M., Lee, Y., Park, J., Jung, H., & Lee, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114990 · Cited by 232
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System
Pattipeiluhu, R., Arias‐Alpizar, G., Basha, G., Chan, K. Y. T., Bussmann, J., Sharp, T. H., Moradi, M., Sommerdijk, N., Harris, E. N., Cullis, P. R., et al. (2022) · Advanced Materials · doi:10.1002/adma.202201095 · Cited by 194
Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines
Swetha, K., Kotla, N. G., Tunki, L., Jayaraj, A., Bhargava, S. K., Hu, H., Bonam, S. R., & Kurapati, R. (2023) · Vaccines · doi:10.3390/vaccines11030658 · Cited by 196
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F. H., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 190
Drug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193
Kheirolomoom, A., Kare, A. J., Ingham, E. S., Paulmurugan, R., Robinson, E. R., Baikoghli, M., Inayathullah, M., Seo, J. W., Wang, J., Fite, B. Z., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121339 · Cited by 171
Nanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 177
Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery
Herrera‐Barrera, M., Kim, J., Eygeris, Y., Jozić, A., & Sahay, G. (2021) · Biomaterials Science · doi:10.1039/d0bm01947j · Cited by 180
Research Advances on the Stability of mRNA Vaccines
Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., & Xu, M. (2023) · Viruses · doi:10.3390/v15030668 · Cited by 177
Liu, M., Wang, Y., Zhang, Y.-B., Hu, D., Tang, L., Zhou, B., & Yang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02112-8 · Cited by 189
Nanostructured particles assembled from natural building blocks for advanced therapies
Ju, Y., Liao, H., Richardson, J. J., Guo, J., & Caruso, F. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00343g · Cited by 157
Munson, M. J., O’Driscoll, G., da Silva, A. M., Lázaro‐Ibáñez, E., Gallud, A., Wilson, J. T., Collén, A., Esbjörner, E. K., & Sabirsh, A. (2021) · Communications Biology · doi:10.1038/s42003-021-01728-8 · Cited by 160
Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles
Hatit, M. Z. C., Lokugamage, M. P., Dobrowolski, C. N., Paunovska, K., Ni, H., Zhao, K., Vanover, D. A., Beyersdorf, J. P., Peck, H. E., Loughrey, D., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-021-01030-y · Cited by 158
Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer
Zhou, L., Hou, B., Wang, D., Sun, F. Z., Song, R., Shao, Q., Wang, H., Yu, H., & Li, Y. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01140 · Cited by 139
Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid
Jia, Y., Wang, X., Li, L., Li, F., Zhang, J., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305300 · Cited by 147
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Nanomaterials for Therapeutic RNA Delivery
Han, X., Mitchell, M. J., & Nie, G. (2020) · Matter · doi:10.1016/j.matt.2020.09.020 · Cited by 139
Guo, J., Wan, T. Y., Li, B., Pan, Q., Xin, H., Qiu, Y., & Yuan, P. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01648 · Cited by 134
Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
Patel, S. K., Billingsley, M. M., Frazee, C. P., Han, X., Swingle, K. L., Qin, J., Alameh, M., Wang, K., Weissman, D., & Mitchell, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.020 · Cited by 142
Seo, Y., Lim, H., Park, H., Yu, J., An, J., Yoo, H. Y., & Lee, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030772 · Cited by 137
Liu, K., Nilsson, R. G., Lázaro‐Ibáñez, E., Duàn, H., Miliotis, T., Strimfors, M., Lerche, M., Ribeiro, A. R. S., Ulander, J., Lindén, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39768-9 · Cited by 141
Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles
Xu, E., Saltzman, W. M., & Piotrowski-Daspit, A. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.038 · Cited by 139
Lipid carriers for mRNA delivery
Zhang, W., Jiang, Y., He, Y., Boucetta, H., Wu, J., Chen, Z., & He, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.026 · Cited by 134
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130
Cornebise, M., Narayanan, E., Xia, Y., Acosta, E. P., Ci, L., Koch, H., Milton, J., Sabnis, S., Salerno, T., & Benenato, K. E. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202106727 · Cited by 134
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Wei, P.-S., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., Ma, Z., Tsai, Y.-H., & Mei, K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.030 · Cited by 138
Microfluidic Manufacture of Lipid-Based Nanomedicines
Osouli-Bostanabad, K., Puliga, S., Serrano, D. R., Bucchi, A., Halbert, G., & Lalatsa, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091940 · Cited by 137
Pattipeiluhu, R., Zeng, Y., Hendrix, M. M. R. M., Voets, I. K., Kros, A., & Sharp, T. H. (2024) · Nature Communications · doi:10.1038/s41467-024-45666-5 · Cited by 132
Optimal self-assembly of lipid nanoparticles (LNP) in a ring micromixer
Ripoll, M., Martin, E. A., Enot, M., Robbe, O., Rapisarda, C., Nicolai, M., Deliot, A., Tabeling, P., Authelin, J., Nakach, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13112-5 · Cited by 105
LXR signaling controls homeostatic dendritic cell maturation
Bosteels, V., Maréchal, S., Nolf, C. D., Rennen, S., Maelfait, J., Tavernier, S. J., Vetters, J., Velde, E. V. D., Fayazpour, F., Deswarte, K., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add3955 · Cited by 114
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 124
Non-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety
Vlatkovic, I. (2021) · Biomedicines · doi:10.3390/biomedicines9050530 · Cited by 112
Current landscape of mRNA technologies and delivery systems for new modality therapeutics
Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 124
Hammel, M., Fan, Y., Sarode, A., Byrnes, A. E., Zang, N., Kou, P., Nagapudi, K., Leung, D., Hoogenraad, C. C., Chen, T., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c01186 · Cited by 107
Lipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective
Rehman, M., Tahir, N., Sohail, M. F., Qadri, M. U., Duarte, S. O. D., Brandão, P., Esteves, T., Javed, I., & Fonte, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111376 · Cited by 112
Lipid Nanoparticle Technologies for Nucleic Acid Delivery: A Nanoarchitectonics Perspective
Ferhan, A. R., Park, S.-H., Park, H., Tae, H., Jackman, J. A., & Cho, N. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202203669 · Cited by 103
Lipid nanoparticles: Composition, formulation, and application
Xu, S., Hu, Z., Song, F., Xu, Y. G., & Han, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101463 · Cited by 115
Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery
Cárdenas, M., Campbell, R. A., Arteta, M. Y., Lawrence, M. J., & Sebastiani, F. (2023) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2023.101705 · Cited by 108
Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids
Bader, J., Brigger, F., & Leroux, J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115461 · Cited by 110
Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity
Luozhong, S., Liu, P., Li, R., Yuan, Z., Debley, E. L., Chen, Y., Hu, Y., Cao, Z., Cui, M., McIlhenny, K., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02240-8 · Cited by 106
Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 95
Han, X., Alameh, M., Gong, N., Xue, L., Ghattas, M., Bojja, G., Xu, J., Zhao, G., Warzecha, C. C., Padilla, M. S., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01557-2 · Cited by 100
Algarni, A., Pilkington, E. H., Suys, E. J. A., Al-Wassiti, H. A., Pouton, C. W., & Truong, N. P. (2022) · Biomaterials Science · doi:10.1039/d2bm00168c · Cited by 95
Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects
Liu, Y., Huang, Y., He, G., Guo, C., Dong, J., & Wu, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810166 · Cited by 100
Xiong, H., Liu, S., Wei, T., Cheng, Q., & Siegwart, D. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.030 · Cited by 92
Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells
Vavassori, V., Ferrari, S., Beretta, S., Asperti, C., Albano, L., Annoni, A., Gaddoni, C., Varesi, A., Soldi, M., Cuomo, A., et al. (2023) · Blood · doi:10.1182/blood.2022019333 · Cited by 95
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 96
Designing lipid nanoparticles using a transformer-based neural network
Chan, A., Kirtane, A. R., Qu, Q. R., Huang, X., Woo, J., Subramanian, D. A., Dey, R., Semalty, R., Bernstock, J. D., Ahmed, T., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01975-4 · Cited by 106
A Biopharmaceutical Perspective on Higher-Order Structure and Thermal Stability of mRNA Vaccines
Kloczewiak, M. A., Banks, J. M., Jin, L., & Brader, M. L. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00092 · Cited by 90
Recent progress in mRNA cancer vaccines
Yao, R., Xie, C., & Xia, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2307187 · Cited by 91
Light-induced liposomes for cancer therapeutics
Chen, W., Goldys, E. M., & Deng, W. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101052 · Cited by 87
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
Kalita, T., Dezfouli, S. A., Pandey, L. M., & Uludağ, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112520 · Cited by 90
Beyond the Endosomal Bottleneck: Understanding the Efficiency of mRNA/LNP Delivery
Liu, H., Chen, M. Z., Payne, T. J., Porter, C. J. H., Pouton, C. W., & Johnston, A. P. R. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202404510 · Cited by 90
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 104
Rational design of anti‐inflammatory lipid nanoparticles for mRNA delivery
Zhang, H., Han, X., Alameh, M., Shepherd, S. J., Padilla, M. S., Xue, L., Butowska, K., Weissman, D., & Mitchell, M. J. (2022) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37356 · Cited by 83
Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery
Patel, S. K., Billingsley, M. M., Mukalel, A. J., Thatte, A. S., Hamilton, A. G., Gong, N., El-Mayta, R. D., Safford, H. C., Merolle, M. I., & Mitchell, M. J. (2023) · Theranostics · doi:10.7150/thno.89913 · Cited by 82
Catenacci, L., Rossi, R., Sechi, F., Buonocore, D., Sorrenti, M., Perteghella, S., Peviani, M., & Bonferoni, M. C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121521 · Cited by 86
mRNA in cancer immunotherapy: beyond a source of antigen
Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 85
Kawaguchi, M., Noda, M., Ono, A., Kamiya, M., Matsumoto, M., Tsurumaru, M., Mizukami, S., Mukai, H., & Kawakami, S. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.12.026 · Cited by 83
Metadata
- Authors
- Patel, S., Ashwanikumar, N., Robinson, E., Xia, Y., Mihai, C., Griffith, J. P., Hou, S., Esposito, A. A., Ketova, T., Welsher, K., Joyal, J. L., Almarsson, Ö., & Sahay, G.
- Affiliations
- Oregon State University (US)
- Moderna Therapeutics (United States) (US)
- Duke University (US)
- Corresponding author
- Sahay, Gaurav
- ORCID
- Venue
- Nature Communications
- Published
- 2020-02-20
- Volume
- 11
- Issue
- 1
- Pages
- 983-983
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7033178
- OpenAlex
- W3006764150
- Cited by
- 601
- References
- 72
- Citations by year
- 2026: 108 · 2025: 156 · 2024: 127 · 2023: 72 · 2022: 64 · 2021: 50 · 2020: 23
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-07-06)
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (1R15EB021581)
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (1R01HL146736-01)
- Cystic Fibrosis Foundation (SAHAY18G0)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- cholesterol analogues, lipid nanoparticles, mRNA delivery, endosomal escape, nanoparticle morphology, transfection, cellular uptake, intracellular diffusion, structure-activity relationship
- MeSH terms
- RAW 264.7 Cells, Animals, Biological Transport, Active, Cell Line, Cholesterol, HeLa Cells, Humans, Lipids, Endosomes, RNA, Messenger, Sitosterols, Transfection, X-Ray Diffraction, Cryoelectron Microscopy, Mice, Nanoparticles, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review